Product
Vemurafenib
Aliases
BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX4032, PLX-4032, RG7204 (9 other aliases)
Name
ZELBORAF
FDA Approved
Yes
39 clinical trials
1 organization
1 drug
106 indications
1 document
Indication
MelanomaIndication
CancerIndication
Solid TumorsIndication
Bile Duct CancerIndication
Salivary CancerIndication
Bladder CancerIndication
Lung CancerIndication
Metastatic MelanomaIndication
Colorectal cancerIndication
Solid TumorIndication
Cancer of Unknown Primary SiteIndication
Malignant NeoplasmIndication
Non-Hodgkin LymphomaIndication
Stage IV Non-Hodgkin LymphomaIndication
Histiocytic SarcomaIndication
Juvenile XanthogranulomaIndication
Langerhans Cell HistiocytosisIndication
Malignant GliomaIndication
Recurrent Childhood RhabdomyosarcomaIndication
EpendymomaIndication
Ewing SarcomaIndication
Recurrent GliomaIndication
HepatoblastomaIndication
Recurrent Langerhans Cell HistiocytosisIndication
Recurrent Malignant Germ Cell TumorIndication
Recurrent Malignant Solid NeoplasmIndication
MedulloblastomaIndication
NeuroblastomaIndication
OsteosarcomaIndication
Recurrent rhabdoid tumorIndication
Soft Tissue SarcomaIndication
GliomaIndication
Malignant Germ Cell TumorIndication
Malignant Solid NeoplasmIndication
Refractory Non-Hodgkin LymphomaIndication
Rhabdoid TumorIndication
RhabdomyosarcomaIndication
Soft Tissue Sarcoma AJCC v7Indication
Osteosarcoma AJCC v7Indication
Stage IV Soft Tissue Sarcoma AJCC v7Indication
Wilms tumorIndication
Skin CancerIndication
Pancreatic CancerIndication
Breast CancerIndication
Gastrointestinal CancerIndication
Breast CarcinomaIndication
Ovarian CancerIndication
Pancreatic CarcinomaIndication
Prostate CancerIndication
Advanced SarcomaIndication
Breast Cancer, Stage IVIndication
Recurrent Ovarian CarcinomaIndication
Stage III Ovarian Cancer AJCC v8Indication
Stage III Pancreatic CancerIndication
Stage IV Ovarian CancerIndication
Thyroid CancerIndication
Advanced CancerIndication
Haematological MalignancyIndication
Hairy Cell LeukemiaIndication
LeukemiaIndication
Hairy CellIndication
BRAFIndication
KRAS wild type AlleleIndication
Metastatic Malignant Solid NeoplasmIndication
Colorectal CancerIndication
NeoplasmIndication
HistiocytosisIndication
PapillaryIndication
Laryngeal NeoplasmsIndication
cancerIndication
Non-Small Cell LungIndication
Multiple MyelomaIndication
Erdheim-Chester DiseaseIndication
AnaplasticIndication
Cutaneous MelanomaIndication
Stage IIIC Cutaneous Melanoma AJCC v8Indication
Stage IIID Cutaneous Melanoma AJCC v8Indication
FollicularIndication
Thyroid Cancer (Follicular Cell)Indication
BRAF V600E Mutation PositiveIndication
Malignant Melanoma Stage IVIndication
BRAF V600 MutationIndication
Brain MetastasesIndication
Advanced Solid TumorIndication
Metastatic CancerIndication
BRAF V600E Mutation PresentIndication
Papillary CraniopharyngiomaIndication
Colorectal Cancer MetastaticIndication
Childhood Non-Hodgkin LymphomaIndication
hepatoblastomaIndication
Germ Cell TumorIndication
Metastatic Thyroid CancerIndication
Thyroid CarcinomaIndication
Anaplastic Thyroid CarcinomaIndication
Hematologic CancerIndication
Metastatic cancerDrug
VemurafenibIndication
NSCLCClinical trial
A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable Locally Advanced or Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2019-10-11
Clinical trial
My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These AgentsStatus: Completed, Estimated PCD: 2023-05-24
Clinical trial
NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)Status: Recruiting, Estimated PCD: 2028-07-05
Clinical trial
Comparative Effectiveness of Different Targeted Therapies for BRAF-mutated Unresectable/Metastatic Melanoma in the United StatesStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase II Two Cohort Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System MetastasesStatus: Completed, Estimated PCD: 2021-06-07
Clinical trial
A Phase I, Single Arm, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of HL-085 Plus Vemurafenib in Patients With BRAF V600 Mutant Advanced Solid TumorStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase Ⅱ, Multicenter Open-label Study to Investigate the Efficacy and Safety of HL-085 Combined With Vemurafenib in Patients With Metastatic Colorectal Cancer (mCRC)Status: Recruiting, Estimated PCD: 2024-01-20
Clinical trial
A Single-arm, Multi-center Phase II Trial to Evaluate the Efficacy and Safety of the Combination of HL-085 and Vemurafenib in Advanced Melanoma Patients With BRAF V600E/K MutationStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2023-02-14
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening ProtocolStatus: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
Phase I Study of Escalating Doses of XL888 With Vemurafenib Plus Cobimetinib for Patients With Unresectable BRAF Mutated Stage III/IV MelanomaStatus: Active (not recruiting), Estimated PCD: 2019-10-31
Clinical trial
A Phase II Trial of Vemurafenib in Combination With Sorafenib to Treat Patients With Advanced KRAS Mutated Pancreatic Cancer: Targeting RAF Dimers to Suppress Oncogenic RAS Signaling (The Dr. Nate Nieto Study)Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
"NEOadjuvant Plus Adjuvant Therapy With Combination or Sequence of Vemurafenib, cobImetinib, and atezolizuMab in Patients With High-risk, Surgically Resectable BRAF Mutated and Wild-type Melanoma"Status: Active (not recruiting), Estimated PCD: 2023-12-15
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)Status: Withdrawn, Estimated PCD: 2026-05-31
Clinical trial
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity - DARWINIIStatus: Active (not recruiting), Estimated PCD: 2026-05-01
Clinical trial
Pharmacodynamic Study of Vemurafenib in the Neoadjuvant Setting in Patients With Locally Advanced Thyroid CancerStatus: Active (not recruiting), Estimated PCD: 2026-09-30
Clinical trial
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to Determine the Efficacy in Treatment of Advanced Cancers With a Known Molecular ProfileStatus: Recruiting, Estimated PCD: 2026-11-25
Clinical trial
Pediatric Neuro-Oncology Consortium (PNOC)-002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults With Recurrent/Refractory BRAFV600E- or BRAF Ins T Mutant Brain TumorsStatus: Active (not recruiting), Estimated PCD: 2018-12-05
Clinical trial
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)Status: Recruiting, Estimated PCD: 2028-08-03
Clinical trial
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell LeukemiaStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase I Trial of Vemurafenib in Combination With Cetuximab and Irinotecan in Patients With BRAF V600 Mutant Advanced Solid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Clinical trial
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory HistiocytosisStatus: Recruiting, Estimated PCD: 2026-03-30
Clinical trial
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
Neoadjuvant Therapy for Patients With High Risk Stage III Melanoma: A Pilot Clinical TrialStatus: Recruiting, Estimated PCD: 2025-06-29
Clinical trial
A Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid CancersStatus: Completed, Estimated PCD: 2023-09-29
Clinical trial
A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaStatus: Completed, Estimated PCD: 2024-03-01
Clinical trial
An Open-label Phase II Multicenter Study of Vemurafenib (Zelboraf®) Plus Cobimetinib (Cotellic®) After Radiosurgery in Patients With Active BRAF-V600-mutant Melanoma Brain MetastasesStatus: Terminated, Estimated PCD: 2023-02-10
Clinical trial
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot StudyStatus: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
KOrean Precision Medicine Networking Group Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors IIStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyStatus: Terminated, Estimated PCD: 2022-12-30
Clinical trial
Phase II Trial of BRAF/MEK Inhibitors in Papillary CraniopharyngiomasStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
The Prospective Non-randomized Phase II Clinical Trial of Vemurafenib in Combination With Cytarabine and 2-chlorodeoxyadenosine in Children With Langerhans-cell Hisitocytosis With BRAF V600E MutationStatus: Recruiting, Estimated PCD: 2023-04-01
Clinical trial
A Phase Ia/II, Single Arm Trial on the Efficacy of Vemurafenib in Combination With Irinotecan and Cetuximab in BRAF V600E-Mutant Metastatic Colorectal CancerStatus: Completed, Estimated PCD: 2021-12-31
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 MutationsStatus: Active (not recruiting), Estimated PCD: 2022-06-30
Clinical trial
Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid CarcinomasStatus: Active (not recruiting), Estimated PCD: 2025-07-31
Clinical trial
Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic AlterationsStatus: Active (not recruiting), Estimated PCD: 2019-05-07
Clinical trial
Continuous ReAssessment With Flexible ExTension in Rare Malignancies - CRAFT: The NCT-PMO-1602 Phase II TrialStatus: Recruiting, Estimated PCD: 2025-06-30
Document
DailyMed Label: ZELBORAFOrganization
Genentech, Inc.